Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

92.00 -0.47 (-0.51%)
Streaming Delayed Price Updated: 3:47 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
61 62 Next >
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
Exposures COVID-19
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
Jeff Bezos Vs. Elon Musk Space Contract Lawsuit, Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations, Tesla Rival XPeng's August Deliveries Zooms 43%: Today's Top Stories
Tech Crunch 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ: 
Via Benzinga
Exposures COVID-19
BioNTech Unusual Options Activity For August 30
Via Benzinga
Expert Ratings for BioNTech
Via Benzinga
BioNTech Unusual Options Activity For August 21
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
What's Going On With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday. 
Via Benzinga
What's Happening With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 3.28% to $101.73 Tuesday afternoon as the stock rebounds after falling on Monday. 
Via Benzinga
BioNTech Se (BNTX) Q2 2023 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why Novavax Stock Was So Healthy on Monday
As the coronavirus threat rises, so too does the vaccine maker's value to investors. 
Via The Motley Fool
Exposures COVID-19
Why BioNTech Shares Are Rising During Monday's Session
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by some 2.25% to $120.26 Monday. The stock is gaining today amid rising COVID-19 cases in the U.S. 
Via Benzinga
Exposures COVID-19
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
COVID Is Making a Comeback: Should You Buy These 2 Stocks?
Can these companies keep up their recent momentum? 
Via The Motley Fool
Exposures COVID-19
Novavax (NVAX) Stock Is Getting Ready to Rally Again
Novavax only has an Emergency Use Authorization and faces a struggle to get paid for its protein-based Covid shot. 
Via InvestorPlace
Exposures COVID-19
Why Moderna, BioNTech SE, and Novavax Surged Today
The companies have developed vaccines for the current dominant strain of COVID, and the Biden administration is getting behind a new booster campaign. 
Via The Motley Fool
Exposures COVID-19
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling. 
Via The Motley Fool
Why Moderna Stock Sunk Today
Moderna, Inc. (NASDAQ: MRNA) shares are trading lower on Monday. 
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Moderna, BioNTech And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones falling around 150 points on Monday. Here are some big stocks recording gains in today’s session. Genelux Corporation (NASDAQ: GNLX) gained 19.2% to $28.58.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris' Advance
The companies are hoping to launch their updated Covid shots in September. 
Via Investor's Business Daily
Exposures COVID-19
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies... 
Via Benzinga
Exposures COVID-19
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
Via Benzinga
Exposures COVID-19
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23
BioNTech SE (NASDAQ: BNTX) has reported Q2 revenues of €167.7 million, sharply down from €3.2 billion a year ago 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
61 62 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.